肝硬化患者初级止血知识的演变:综合综述
本文综述肝硬化患者初级止血的复杂改变,包括血小板减少、血小板功能多重改变及血管性血友病因子水平升高。当前理论认为肝硬化存在再平衡止血,严重血小板减少不预示出血风险,也不决定术前预防需求。血管性血友病因子抗原与ADP诱导的全血血小板聚集经血小板计数标准化(VITRO评分和PLT比值)是预测失代偿和生存的有前景生物标志物。
要点
- 肝硬化患者初级止血改变复杂,兼具低凝与高凝特征,当前理论认为再平衡止血。
- 严重血小板减少不预示侵入性操作出血风险,不决定术前预防需求。
- VITRO评分和PLT比值是预测肝硬化失代偿和生存的有前景生物标志物。
核心结论
- 肝硬化患者存在再平衡止血,严重血小板减少不预示出血风险,也不决定术前预防需求。
研究设计与样本
- 综合综述,回顾肝硬化患者血小板和初级止血的复杂改变及其潜在临床意义。
主要发现
- 肝硬化初级止血改变包括血小板减少、血小板功能多重改变及血浆血管性血友病因子水平升高。
- 严重血小板减少不预示侵入性操作出血风险,也不决定术前预防需求。
- 血小板功能改变与出血/血栓形成的关联尚未完全明确,需更多研究以改善失代偿肝硬化风险分层。
- 血管性血友病因子抗原与ADP诱导的全血血小板聚集经血小板计数标准化(VITRO评分和PLT比值)是预测代偿和失代偿患者肝失代偿风险和生存的有前景生物标志物。
临床怎么用
- 严重血小板减少不决定术前预防需求,应综合评估止血损伤、失代偿严重程度、全身炎症及急性肾损伤和细菌感染等额外因素。
局限性
- 血小板功能改变与出血/血栓形成的关联尚未完全明确,需更多研究以改善失代偿肝硬化风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with cirrhosis develop complex alterations in primary hemostasis that include both hypocoagulable and hypercoagulable features. This includes thrombocytopenia, multiple alterations of platelet function, and increased plasma levels of von Willebrand factor. Contrary to the historical view that platelet dysfunction in cirrhosis might be responsible for an increased bleeding tendency, the current theory posits a rebalanced hemostasis in patients with cirrhosis. Severe thrombocytopenia is not indicative of the bleeding risk in patients undergoing invasive procedures and does not dictate per se the need for pre-procedural prophylaxis. A more comprehensive and individualized risk assessment should combine hemostatic impairment, the severity of decompensation and systemic inflammation, and the presence of additional factors that may impair platelet function, such as acute kidney injury and bacterial infections. Although there are multiple, complex alterations of platelet function in cirrhosis, their net effect is not yet fully understood. More investigations evaluating the association between alterations of platelet function and bleeding/thrombosis may improve risk stratification in patients with decompensated cirrhosis. Besides hemostasis, the assessment of von Willebrand factor Ag and ADP-induced, whole-blood platelet aggregation normalized by platelet count (VITRO score and PLT ratio) are promising biomarkers to predict the risk of hepatic decompensation and survival in both compensated and decompensated patients. Further investigations into the in vivo interplay between platelets, circulating blood elements, and endothelial cells may help advance our understanding of cirrhotic coagulopathy. Here, we review the complex changes in platelets and primary hemostasis in cirrhosis and their potential clinical implications.
引用
- Zanetto A, Campello E, Senzolo M, et al. The evolving knowledge on primary hemostasis in patients with cirrhosis: A comprehensive review. Hepatology. 2023. PMID: 36825598. doi:10.1097/HEP.0000000000000349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。